OBJECTIVE: To evaluate the safety and tolerability of dalfampridine extended release (D-ER) in participants with chronic post-ischemic stroke deficits, and to assess for potential drug activity on sensorimotor function. METHODS: Using a double-blind, placebo-controlled, cross-over design, participants were randomized to placebo/D-ER or D-ER/placebo sequences and given D-ER 10 mg or placebo twice daily. Key inclusion criteria were: ischemic stroke ≥ 6 months, Fugl-Meyer Assessmentlower extremity motor score ≤ 28, ability to complete Timed 25-Foot Walk (T25FW). The primary outcome was safety and tolerability. The key exploratory measure was walking speed (T25FW). Other assessments were: Box and Block, and Grip and Pinch tests; Functional Independence Measure. Full-crossover data were analyzed using mixed-effects model. RESULTS: A total of 83 participants were randomized: 70 completed and 13 discontinued the study. Adverse events were consistent with previous D-ER trials; no new safety signals were observed. Four participants experienced serious adverse events: 3 seizures (1 placebo, 2 D-ER), 1 was secondary to intentional overdose. Most common treatment-emergent adverse events were: dizziness, nausea, arthralgia and fatigue. Mixed-effects analysis showed an effect for D-ER vs. placebo in improving walking speed (0.21 vs. 0.10 ft/s; p = 0.027). CONCLUSIONS: D-ER was generally well tolerated in participants with chronic stroke deficits. Potential drug activity on lower extremity sensorimotor function, with an improvement in walking speed, was seen.
RCT Entities:
OBJECTIVE: To evaluate the safety and tolerability of dalfampridine extended release (D-ER) in participants with chronic post-ischemic stroke deficits, and to assess for potential drug activity on sensorimotor function. METHODS: Using a double-blind, placebo-controlled, cross-over design, participants were randomized to placebo/D-ER or D-ER/placebo sequences and given D-ER 10 mg or placebo twice daily. Key inclusion criteria were: ischemic stroke ≥ 6 months, Fugl-Meyer Assessment lower extremity motor score ≤ 28, ability to complete Timed 25-Foot Walk (T25FW). The primary outcome was safety and tolerability. The key exploratory measure was walking speed (T25FW). Other assessments were: Box and Block, and Grip and Pinch tests; Functional Independence Measure. Full-crossover data were analyzed using mixed-effects model. RESULTS: A total of 83 participants were randomized: 70 completed and 13 discontinued the study. Adverse events were consistent with previous D-ER trials; no new safety signals were observed. Four participants experienced serious adverse events: 3 seizures (1 placebo, 2 D-ER), 1 was secondary to intentional overdose. Most common treatment-emergent adverse events were: dizziness, nausea, arthralgia and fatigue. Mixed-effects analysis showed an effect for D-ER vs. placebo in improving walking speed (0.21 vs. 0.10 ft/s; p = 0.027). CONCLUSIONS: D-ER was generally well tolerated in participants with chronic stroke deficits. Potential drug activity on lower extremity sensorimotor function, with an improvement in walking speed, was seen.
Authors: Anil Sindhurakar; Asht M Mishra; Disha Gupta; Jennifer F Iaci; Tom J Parry; Jason B Carmel Journal: Neurorehabil Neural Repair Date: 2017-01-20 Impact factor: 3.919
Authors: Joshua Silverstein; Mar Cortes; Katherine Zoe Tsagaris; Alejandra Climent; Linda M Gerber; Clara Oromendia; Pasquale Fonzetti; Rajiv R Ratan; Tomoko Kitago; Marco Iacoboni; Allan Wu; Bruce Dobkin; Dylan J Edwards Journal: Front Neurosci Date: 2019-08-02 Impact factor: 4.677
Authors: Nicolas J Guehl; Karla M Ramos-Torres; Clas Linnman; Sung-Hyun Moon; Maeva Dhaynaut; Moses Q Wilks; Paul K Han; Chao Ma; Ramesh Neelamegam; Yu-Peng Zhou; Brian Popko; John A Correia; Daniel S Reich; Georges El Fakhri; Peter Herscovitch; Marc D Normandin; Pedro Brugarolas Journal: J Cereb Blood Flow Metab Date: 2020-10-22 Impact factor: 6.200
Authors: Stephen J Page; Scott E Kasner; Marcia Bockbrader; Mark Goldstein; Seth P Finklestein; MingMing Ning; Waleed H El-Feky; Christina A Wilson; Holly Roberts Journal: Restor Neurol Neurosci Date: 2020 Impact factor: 2.406